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Abstract
Opioid abuse and overdose are associated with substantial morbidity and mortality rates,
as well as social and economic costs. The purpose of this study was to evaluate the
independent and interactive effects of state-sponsored prescription drug monitoring
program (PDMP) trained healthcare providers and community-based naloxone
distribution program related factors in the states of Florida and Georgia for the prevention
and reduction of prescription opioid use disorder, overdose, and deaths. The research
theory adopted was the socio-ecological model with an emphasis on risk factors such as
age. The study used secondary data from 2014 to 2018 from the Florida and Georgia
Departments of Health. The statistical analysis results from one-way ANOVA and
multiple linear regression revealed that there is a direct association between the number
of state-sponsored PDMPs trained healthcare providers per year and the number of
reported opioid overdoses, the number of opioid addiction treatment admissions, and the
number of deaths attributed to opioid overdose-related deaths per year among adults 25 to
64 years. The results also showed that there is an association between community-based
naloxone distribution, the number of reported opioid overdoses, the number of opioid
addiction treatment admissions, and the number of deaths attributed to opioid
misuse/overdose per year among adults 25 to 64 years. The positive social impact of the
study is that PDMPs, the education of healthcare providers, community use of naloxone,
and practice guidelines will reduce misuse, abuse, addiction, diversion, and false
acquisition of prescription opioids.
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Section 1: Foundation of the Study and Literature Review
Introduction
The purpose of this study was to assess how various state-sponsored prescription
drugs monitoring programs (PDMPs) training of healthcare providers on prescribing and
dispensing of opioid drugs and community-based naloxone distribution program
(CBNDP) events have contributed to the reduction of prescription drug use disorder and
overdose. Opiate overdose persists as a significant public health problem, contributing to
substantial morbidity and mortality among opiate users. In 2016, about 2 million
Americans aged 12 and older admitted having an opioid use disorder (Rando et al., 2015;
Reinhart et al., 2018). Drug overdose is currently one of the leading causes of preventable
mortality in the United States (Rando et al., 2015). Opioids are the most common
substances found in the single or poly cause of death (Rando et al., 2015).
Opioid overdose is one of the leading causes of injury-related death among
Americans (age 25 to 64 years). From 1999 to 2018, there were more than 450,000 opioid
overdose deaths. In 2018 alone, there were 47,000 opioid-related deaths in the US
(Wilson et al. 2020). Approximately 45 deaths per day in the United States have been
attributed to prescription opioids (Rando et al., 2015). Most of the overdose deaths are
due to prescription opioid analgesics such as oxycodone, methadone, and hydrocodone
(Li et al., 2014).
Opioid overdose is a significant public health concern that affects a diverse group
of individuals across all categories of race, class, and geography. Opioid-related
overdoses are spreading demographically and geographically such as from urban areas to
suburban and rural regions. Research has shown that overdose mortality is on the rise
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among non-Hispanic Whites, women, adolescents, young adults, and those with a history
of chronic pain and depression (Colucci et al., 2014). Moreover, misuse and abuse of
opioid analgesics have adverse health implications, including psychiatric illness (Colucci
et al., 2014).
According to Patrick et al. (2016), over 47,000 people died in the United States
from drug abuse in 2014 alone, and 61% of those deaths were prescription opioid related.
It is estimated that prescription overdose fatalities represent 63% of all overdose
mortalities (Rudd, 2016). Naloxone has been frequently used to pharmacologically
reverse overdoses by emergency service workers as well as peers or family members of
overdose victims (Abraham et al., 2017). It is best to intervene within an hour of the
onset of overdose symptoms (Abraham et al., 2017).
The introduction of different state PDMPs with federal government funding
assistance established statewide electronic databases of dispensed controlled substances
(Li et al., 2014). Most states currently have (a) PDMPs, (b) prescription drug take-back
days, (c) safe opioid prescribing guidelines, (d) education programs that seek to reduce
opioid misuse and monitor and limit physicians and other healthcare providers on the
number of opioids that can be prescribed or dispensed by using checks such as drug
utilization review and prior authorization in insurance reimbursements, (e) mandatory use
of state recommended guidelines and PDMPs, and (f) the distribution and administration
of naloxone to at-risk patients (Faul et al., 2017). In this study, I sought to bring a
positive change or social impact by seeking to inform and educate lawmakers, local
authorities, and community leaders on the need to reduce and prevent prescription opioid
use disorder and overdose in Florida and Georgia. This section includes the problem
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statement, research questions, purpose of the study, literature review, definitions,
assumptions, and delimitations.
Problem Statement
In recent years there has been an increase in the use of prescription opioids in the
treatment of chronic non-cancer pain such as back pain and osteoarthritis despite the lack
of long-term effectiveness and the risk of abuse (Centers for Disease Control and
Prevention [CDC], 2019). According to the CDC (2019), opioid prescription overdose
causes more than 34,000 deaths and 1.2 million emergency department visits annually.
Most of the overdose deaths are due to prescription opioid analgesics such as oxycodone,
methadone, and hydrocodone (Li et al., 2014).
In 2015, more than 12 million Americans reported misusing opioid pain relievers
(Abraham et al., 2017). According to the CDC (2018), between 1999 and 2016, there
were more than 630,000 deaths due to drug overdose. In 2016, about 42,000 drug
overdose deaths involved an opioid (CDC, 2018). Additionally, it is estimated that about
115 Americans die daily from an opiate overdose (CDC, 2019).
More than three out of five drug overdose deaths involve an opioid (CDC, 2019).
Overdose deaths from opioids, including prescription opioids and heroin, have increased
by five times since 1999 (CDC, 2019). Over 50% of those deaths were from prescription
opioids (CDC, 2019). It is also alarming to know that the annual number of prescriptions
for opioid analgesics has increased from approximately 75 million to almost 210 million
in the past 20 years (CDC, 2019).
The per capita consumption of prescription opioids has increased from 74
milligrams (mg) to 369 mg in the last decade; hence, an increase in overdose mortality
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(Li et al., 2014). Furthermore, research shows that about 25 million people are involved
in the non-medical use of pain relievers in the past decade (Rutkow et al., 2015).
Overdose related deaths are concentrated among the poor, racial and ethnic minorities,
and individuals cycling in and out of the criminal justice system (Rutkow et al., 2015).
Gap in Research
Research on naloxone distribution and prescription overdose is limited. Some
policymakers have argued that providing naloxone to opiate abusers may increase opioid
use and delay admission to treatment centers (see Doe-Smith, 2014; Rowe et al., 2015).
PDMPs are created to monitor controlled prescription usage and consequently reduce
opioid abuse (Rutkow et al., 2015). There are currently limited studies that demonstrate a
statistically significant association between the two variables (Rutkow et al., 2015).
More so, studies evaluating the effectiveness of PDMPs in reducing opioidrelated mortality are limited. Research evaluating the effectiveness of specific
characteristics of PDMPs is also limited. This could be due to their variability from state
to state. For instance, some states have more controlled substance schedules than the five
schedules from the Drug Enforcement Agency (Faul et al., 2017). Other states do not
classify codeine cough syrups as controlled substances (Patrick et al., 2016).
State policies could also contribute to the lack of research on the effectiveness of
PDMPs. Some states mandate the registration and use of the PDMPs, while others only
require periodic queries and specific algorithms to trigger a comprehensive investigation.
The CDC guidelines on opioid prescribing, however, recommend the regular use of
PDMPs (Finley et al., 2017; Leichtling et al., 2017).
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The opioid epidemic is driven by overprescribing (Faul et al., 2017). Efforts to
prevent prescription opioid overdose include the legislation of different state laws that
limit physicians and other healthcare providers on the number of opioids that can be
prescribed or dispensed, the use of checks such as drug utilization review, and prior
authorization in insurance reimbursements (Faul et al., 2017). The use of state prescribing
guidelines and PDMPs is however mandatory (Faul et al., 2017). Finally, the distribution
and administration of naloxone to at-risk patients is also highly recommended (Faul et al.,
2017).
Purpose of the Study
The purpose of this study was to evaluate and analyze how the number of statesponsored PDMPs trained healthcare providers and CBNDP could affect the misuse,
abuse, addiction, diversion and falsely acquiring of prescription opioids. This quantitative
study emphasized objective measurements, the statistical, mathematical, or numerical
analysis of data collected through manipulating pre-existing statistical data using
computational techniques (see Frost, 2019). Healthcare provider education can reduce
opioid prescribing by at least 40%, and result in fewer ER visits, leading to further
reduction in opioid misuse, abuse, and addiction (Osborn et al., 2017)
The independent variables include: (a) the number of state-sponsored PDMP
trained healthcare providers, (b) the number of naloxone community-based distribution
center opioid prescriptions written per year, (c) the number of naloxone communitybased distribution center prescriptions dispensed per year, (d) the number of naloxone
community-based distribution center opioid prescriptions with MME above 90 written or
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dispensed per year, and (e) naloxone community-based distribution center opioid naïve
patients per year.
The dependent variables include: (a) the number of reported opioid overdoses per
year among adults 25 to 64 years, (b) the number of opioid addiction treatment
admissions per year, and (c) the number of opioid-related deaths per year among adults
25 to 64 years. Controlling variables include the age group of patients and the gender of
the patients.
Research Questions and Hypotheses
RQ1: Is there an association between the number of state-sponsored PDMPs
trained healthcare providers and the number of reported opioid overdoses per year among
adults 25 to 64 years?
H01: There is no association between the number of state-sponsored PDMPs
trained healthcare providers per year and the number of reported opioid overdoses
per year among adults 25 to 64 years.
H11: There is an association between the number of state-sponsored PDMPs
trained healthcare providers per year and the number of reported opioid overdoses
per year among adults 25 to 64 years.
RQ2: Is there an association between the number of state-sponsored PDMPs
trained healthcare providers and the number of opioid addiction treatment admissions per
year among adults 25 to 64 years?
H02: There is no association between the number of state-sponsored PDMPs and
the number of opioid addiction treatment admissions per year among adults 25 to
64 years.
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H12: There is an association between the number of state-sponsored PDMPs
trained physicians and the number of opioid addiction treatment admissions per
year among adults 25 to 64 years.
RQ3: Is there an association between the number of state-sponsored PDMPs
trained healthcare providers and the number of deaths attributed to opioid overdoserelated deaths per year among adults 25 to 64 years?
H03: There is no association between the number of state-sponsored PDMPs
trained healthcare providers per year and the number of opioid overdose-related
deaths per year among adults 25 to 64 years.
H13: There is an association between the number of state-sponsored PDMPs
trained healthcare providers and the number of deaths attributed to opioid
overdose-related deaths per year among adults 25 to 64 years.
RQ4: Is there an association between community-based naloxone distribution and
the number of reported opioid overdoses per year among adults 25 to 64 years?
H04: There no association between community-based naloxone distribution and
the number of reported opioid overdoses per year among adults 25 to 64 years.
H14: There is an association between community-based naloxone distribution and
the number of reported opioid overdose per year among adults 25 to 64 years.
RQ 5: Is there an association between community-based naloxone distribution and
the number of opioid addiction treatment admissions per year among adults 25 to 64
years?
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H05: There is no association between community-based naloxone distribution and
the number of opioid addiction treatment admissions per year among adults 25 to
64 years.
H15: There is an association between community-based naloxone distribution and
the number of opioid addiction treatment admissions per year among adults 25 to
64 years.
RQ6: Is there an association between community-based naloxone distribution and
the number of deaths attributed to opioid misuse/overdose per year among adults 25 to 64
years?
H06: There is no association between community-based naloxone distribution and
the number of deaths attributed to opioid misuse/overdose per year among adults
25 to 64 years.
H16: There is an association between community-based distribution and the
number of deaths attributed to opioid misuse/overdose per year among adults 25
to 64 years.
Theoretical Foundation for the Study
The theoretical base for this study focuses on the social ecological model (SEM),
initially developed by Bronfenbrenner (1992). The theory stipulates that children’s
development is not only affected by their genetic or biological and psychological
makeup, but also by their immediate physical and social environment, as well as the
political and economic conditions in which they live in (Bukatko & Daehler, 2012). SEM
is a multilevel framework which considers the different context and settings with which
an individual interacts. It is based on the premise that individuals are influenced by their
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relationships with others, the institutions, and the communities in which they belong
(CAPT-SAMHSA, 2016).
The SEM theory has been used as a health promotion tool in many public health
interventions, such as obesity, smoke cessation, and diabetes management (CDC, 2019).
SEM theorists emphasized the interactions between the different levels of factors which
are interdependence and how that affects the individual’s health behavior. There are four
levels to the SEM:
•

Individual level: Includes factors specific to the individual, such as age,
education, income, and psychosocial problems. The individuals would be
educated by their healthcare providers when an opioid prescription is written
or dispensed to their peculiar individual characteristics. They would also be
educated on the need to keep a naloxone spray when opioids are prescribed
since a few doses of opioid prescriptions could cause addiction or overdose.

•

Relationship level: Includes an individual’s closest circle (e.g. family
members, peers, and teachers) who contribute to their range of experiences
that may influence behavior. Young people’s behavior is affected by the
strong bond with their parents. This is because parents instill a sense of
purpose in their children. These include the quest to aim high in life, finish
school, get a degree, conform to school regulations, and be law-abiding
citizens, among other values.

•

Community level: Includes the settings in which social relationships occur,
such as schools, workplaces, neighborhoods, and community norms. Other
factors include residential mobility or instability, living in an urban
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environment, and lack of social support or access to resources in dealing with
prescription drug abuse/overdose.
•

Societal level: Includes broader societal factors, such as social, religious, and
cultural norms. Other social factors include health, economic, educational,
social policies, law enforcement, public health education on drug abuse,
availability of addiction treatment centers, state prescription opioid guidelines,
prescription drug take-backs, state-sponsored PDMPs, CBNDPs, and health
providers’ continued education of effective pain management and drug abuse
(CAPT-SAMHSA, 2016).

Figure 1
SEM Model. Adapted from Centers for Disease Control and Prevention; Division of
Nutrition, Physical Activity, and Obesity (DNPAO)
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(Available at https://www.cdc.gov/nccdphp/dnpao/state-local-programs/healthequity/framing-the-issue.html)
This study on state-sponsored PDMPs and CBNDPs considered all the socioecological factors that influence the individual’s health behavior at all levels of the SEM
to reduce the rate of prescription opioid overdose, decrease admissions to addiction
treatment centers, and reduce overall overdose-related fatalities.
Nature of the Study
Study designs are essential for the quality, execution, and interpretation of public
health research. The choice of study design however depends on funding, time
constraints, availability of study participants, and prior research. I deemed the ecological
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or correlation study design to be the appropriate observational study for this research. An
ecological study design compares clusters of people based on their geographical location.
Since this study purposed to use secondary data from the state-sponsored PDMPs’s
database, the ecological or correlation design was adopted. Ecological or correlation
studies are also quick and inexpensive. Additionally, its analysis and presentation are
simple and easy to understand. They are also noted to achieve a broader range of
exposure levels than individual-level studies (Omair, 2015; Thiese, 2014).
This study’s limitations include ecological fallacy or bias, that is, the lack of
individual-level information and the inability to control confounders and possible
inaccuracy of the data used. The unit of analysis is the population, not the individuals.
This means any associations observed between the variables at the population level do
not necessarily translate to the individual level (Aschengrau & Seage, 2014; Omair, 2015;
Thiese, 2014).
The independent variables include the number of state-sponsored PDMPs trained
healthcare providers, opioid prescriptions written and dispensed, the number of opioid
prescriptions with morphine milligram equivalence (MME) above 90 milligrams, and the
number of opioid naïve patients (patients who have never used prescription opioids or
have not used prescription opioids in 6 months or more.)
The dependent variables include the number of reported opioid overdoses per
year, the number of opioid addiction treatment admissions per year, and the number of
opioid-related deaths per year among adults 25 to 64 years. The controlling variables
include the age group and the gender of the patients.
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Table 1
Research Questions, Dependent Variables, and Independent Variables

Research questions

Independent variables

Dependent
variables

RQ 1: Is there an association between
the number of state-sponsored PDMPs
trained healthcare providers per year
and the number of reported opioid
overdoses per year among adults 25 to
64 years?
RQ 2: Is there an association between
the number of state-sponsored PDMPs
trained healthcare providers and the
number of opioid addiction treatment
admissions per year among adults 25 to
64 years?
RQ 3: Is there an association between
the number of state-sponsored PDMPs
trained healthcare providers and the
number of deaths attributed to opioid
overdose-related deaths per year
among adults 25 to 64 years?
RQ 4: Is there an association between
community-based naloxone
distribution and the number of reported
opioid overdoses per year among adults
25 to 64 years?
RQ5: Is there an association between
community-based naloxone
distribution and the number of opioid
addiction treatment admissions per
year among adults 25 to 64 years?

The number of PDMP
trained healthcare providers
per year

The number of
reported
opioid
overdoses per
year

The number of PDMP
trained healthcare providers
per year

The number of
opioid
addiction
treatment
admissions per
year
The number of
opioidoverdoserelated deaths
per year

RQ 6: Is there an association between
community-based naloxone
distribution and the number of deaths
attributed to opioid misuse/overdose
per year among adults 25 to 64 years?

The number of statesponsored PDMPs trained
healthcare providers per
year

Community-based naloxone
distribution (the number of
opioid prescriptions written
and dispensed) per year

The number of
reported
opioid
overdoses per
year
Community-based naloxone The number of
distribution (the number of opioid
opioid prescriptions with
addiction
MME higher than 90mg)
treatment
admissions per
year
Community-based naloxone The number of
distribution (the number of opioid-related
opioid naïve patients)
deaths per
year
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Literature Search Strategy
I used a literature search strategy to identify search engines and databases related
to the research problem. The general search produced existing peer-reviewed papers as
well as government reports on the opioid epidemic. I further searched the SAMSHA and
CDC websites for data and information related to the research problem. The literature
review was also done using peer-reviewed published articles found PubMed, Library of
Congress, ECHBOST, and Medline with full-text abstracts, Cochran Library, Google
Scholar, Pro-Quest Nursing and Allied Health Services, and CINAHL. The search terms
included prescription opioids, abuse, misuse of opioid therapy, drugs, narcotics,
substance abuse, pain management, controlled substances monitoring and diversion,
healthcare, emergency departments, naloxone distribution, prescription drug monitoring
programs, overdose, and drug fatalities.
The scope of the literature search included only peer-reviewed literature published
within the last 5 years. Literature including primary research articles, literature review
articles, secondary research articles with contents relating to either the clinical or
economic effects of prescription opioid abuse, treatment, and overdose, and standing
orders for naloxone distribution in various states and communities, as well as opioid
overdose fatalities were selected and reviewed. The search however excluded nonEnglish articles, newspaper articles, and non-peer-reviewed journals.
Literature Review Related to Key Variables and/or Concepts
This study sought to evaluate and analyze how various state-sponsored PDMP’s
and community-based naloxone distribution programs have contributed to the prevention
or reduction of prescription drug abuse and overdose. The study considered independent
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variables such as age, gender, neighborhoods, and geographical location. The dependent
variables considered included the volume of opioid prescriptions prescribed and
dispensed, the number of healthcare providers trained to use PDMPs and counsel patients
on naloxone use. More so, the number of opioid naïve patients, the number of days for
the supply of prescription opioids, the morphine milligram equivalence of the opioids
prescribed as well as the opioid overdose mortalities were all considered.
Prescription opioid abuse is a growing public health threat especially to the United
States of America (USA). Millions of Americans are struggling with prescription opioid
abuse, with thousands losing their lives due to its overdose. Medical professionals directly
or indirectly influence the prescription opioid abuse epidemic through their prescribing
habits (SAMSHA, 2018). Opioid abuse is also associated with downstream cases of
infections related to intravenous injections such as HIV/AIDS, Hepatitis B, and C
endocarditis, pyogenic spinal infections, osteomyelitis, septic arthritis, and epidural
abscess (Ronan & Herzig, 2016). Hospital admissions concerning prescription opioid
misuse and dependence have nearly doubled between 2000 and 2012. The rate of opioidrelated inpatient stay has increased from 136.8 per 100,000 population in 2005 to 224.6 per
100,000 population in 2014. During this same period, the rate of opioid-related emergency
department visits increased by 99.4 percent, from 89.1 per 100,000 population in 2005 to
177.7 per 100,000 population in 2014 (Weiss et al., 2017).
According to the CDC, the number of opioid prescriptions has more than
quadrupled since the nineties. Research shows that at least one in every four patients given
prescription opioids for the management of non-malignant chronic pain develop some form
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of opioid use disorder, risky behaviors, compulsive use, and physiological dependence
(CDC, 2019; SAMSHA, 2019).
The National Institute on Drug Abuse (NIDA), in partnership with the Appalachian
Regional Commission (ARC), are working together to address the dramatic increase in
prescription opioid drug use in Appalachia. Research has shown that rural communities
along the Appalachian are more likely to have a high incidence of opioid abuse, misuse,
and overdose (Singhal et al., 2016).
Individuals who misuse and abuse opioids tend to live in rural areas and are
generally older than heroin users who tend to live in urban areas. Unintentional opioid
overdose deaths are more common among adults between the ages of 45 to 64 and are even
higher among adults between the ages of 25 and 34 (Pualozzi, 2014). Increases in opioid
overdose fatalities among older individuals are a significant factor in the increases in opioid
prescribing rates. Research shows that people over the age of 65 are prescribed an average
of two opioids per prescription when visiting their doctors (Pualozzi, 2014).

Prevention Interventions
Effective opioid abuse interventions must be directed towards the highest risk
groups. Any form of intervention should involve the individual, family, friends, healthcare
providers, community leaders, and law enforcement agencies (Paulozzi, 2014). Easy access
to state-sponsored Prescription Drug Monitoring Programs (PDMPs) and availability of
naloxone are also key factors to consider. Training of healthcare providers to identify atrisk patients and preventing opioid prescription misuse and abuse is a key strategy to be
adopted in this fight (Volkow & McLellan, 2016).
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According to the CDC (2019), people who are more likely to abuse prescription
opioids exhibit certain physical and psychological behaviors, such as irritability, urgency,
or anxiety. They frequently attempt to obtain prescription opioids from multiple providers
and pharmacies, try to fill opioid prescriptions earlier than time, and continuously change
healthcare providers.
Abuse-deterrent formulations use opioid antagonist agents and chemicals that
induce unpleasant symptoms when taken excessively. Manufacturers also incorporate
physicochemical properties into the drug, making it difficult to extract the active
ingredients from the tablet or capsule (Coplan et al., 2016).
In 2010, the manufacturer of Oxycontin (oxycodone extended release)
reformulated the drug with a polyethylene oxide matrix. This matrix hardens the tablets
which creates physicochemical barriers to deter breaking, crushing, and dissolving, making
it harder to extract oxycodone and decrease the rate of abuse (Coplan et al., 2016).
Kentucky’s rate of OxyContin abuse has reduced from 85% to 30% after the introduction
of the reformulated drug. Data from the National Survey of Drug Use and Health (NSDUH)
published by SAMSHA shows that past year initiation of non-medical use of OxyContin
decreased by 18%, 37%, 26%, and 49% over the years from 2011 to 2014 respectively,
relative to the 695,000 users in 2009 (Coplan et al., 2016). Patients with prescription
opioids with a morphine milligram equivalence (MME) of 100mg/day or more are nine
times at a higher risk of overdose compared to patients with 20mg/day or less (Coe &
Walsh, 2016).
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Socio-Economical and Behavioral Impact
According to the National Epidemiologic Survey on Alcohol and Related
Conditions (NESARC), a survey from 2014 to 2015 shows that young adults aged 18 to 24
are more likely to misuse or abuse opioid prescription and alcohol than adults aged 25 to
64 years (Coplan et al., 2016; Rudd et al., 2016). Research shows that opioid abuse and
overdose are associated with mental health disorders. People with mental health and
behavioral issues such as mood disorders, major depression, dysthymia, mania, and
hypomania, anxiety disorders (e.g. panic disorders with and without agoraphobia), social
phobia, and generalized anxiety disorder are more vulnerable to opioid misuse and abuse.
Patients with a past medical history of substance abuse or prescription opioid use,
mental health issues (e.g., PTSD, depression, anxiety) mentally demanding occupations,
older adults, dysfunctional social environment, and lower self-efficacy are highly
vulnerable to prescription opioid abuse (Chou et al., 2016; Currow et al., 2016; Denenberg
& Curtis, 2016).
The complexity of prescription opioid misuse and abuse is further confounded by
an individual’s demographics such as age, sex, race/ethnicity, educational background,
marital status, and household income (Denenberg & Curtis, 2016). The rise in prescription
opioid misuse and abuse is mostly due to increasing therapeutic use, and newer varying
prescribing guidelines in different states (Brady et al., 2017). According to the Treatment
Episode Data Set, the treatment admission rate for individuals abusing prescription opioids
has increased from 7 to 36 per 100,000 population between 1997 and 2007. Opioid-related
deaths have also increased by more than 124% over the same period (Meyer et al., 2014).
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Research shows that opioid misusers or abusers between the ages of 25 and 64 years
are more likely to utilize medical services, such as the emergency department, mental
health outpatient clinics, and inpatient hospitals (Meyer et al., 2014). According to the Drug
Abuse Warning Network (DAWN), emergency department visits involving prescription
opioid abusers increased by more than 100% from 2004 to 2008. According to the White
House Budget Office, it is estimated that prescription drug abuse, days of work loss,
healthcare providers visits/services, and criminal justice cost the government nearly 300
billion dollars annually (Meyer et al., 2014).
A recent meta-analysis by Brady et al. (2017), indicated that a higher proportion of
males suffer from prescription opioid misuse, abuse, and overdose. Also, individuals of
either gender, aged 25 to 54 are at the highest risk of abuse prescription opioids. Individuals
afflicted with psychotic disorders or had widespread substance abuse issues were more
likely to abuse prescription opioids (Brady et al., 2017).
All patients, including opioid-naïve patients, should be screened for potential risk
of abuse before starting opioid therapy. Patients on opioid therapy should receive education
regarding the safe use, storage, and disposal of prescription opioids. Also, taking the
medications as directed, acquiring them from only one provider, not sharing drugs with
friends and family, and not taking medications with alcohol are important precautions to
be adhered to (Brady et al., 2016).
Long-term use of prescription opioids could precipitate the risk of tolerance,
physical dependence, and withdrawal symptoms when stopped abruptly. Tolerance effects
of medications cause the need to increase the currently prescribed dosages to be effective.
Opioid withdrawal symptoms include sympathetic stimulation, elevated heart rate, and
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blood pressure, pupillary dilation, goosebumps, anxiety, jittery behavior, nausea, diarrhea,
runny nose, yawning, myalgia, and insomnia. These withdrawal symptoms could
sometimes be treated with alpha-blocking agents like clonidine or tapering of opioid
prescriptions (Chou et al., 2016; Currow et al., 2016; Denenberg & Curtis, 2016).
Concurrent use of opioids with neuron-depressants or sedation medications
increases the risk of sedation, hypoventilation, falls, accidents, and sudden unintentional
death. Long-term opioid therapy also increases the risk of cardio-respiratory events or
myocardial infarction in patients with sleep apnea and end-stage respiratory disease (Chou
et al., 2016; Currow et al., 2016; Denenberg & Curtis, 2016).
Research shows that as the dose of the prescription opioid increases, so does the
risk of abuse or dependence. Higher doses are also associated with increased cases of
worker's disability compensation. Prescribing doses less than 120 MME/daily reduces the
rate of mortality due to overdose. Ideally, the appropriate dosing of prescription opioids is
between 40 and 90 MME per day (Manchikanti et al., 2012).
Prescribing opioids to the elderly must be done with caution doses equal to or
higher than 50 MME daily doubles their risk of falls and fractures. Furthermore,
prescribing opioids to pregnant women increases the risk of congenital disabilities, neural
tube defects, congenital heart defects, gastroschisis, poor fetal growth, neonatal opioid
withdrawal syndrome, and stillbirths (Chou et al., 2016; Yazdy et al., 2013).
However, non-pharmacological interventions include relaxation, guided imagery,
acupuncture, massage, acupressure, aromatherapy, reflexology, yoga therapy, music
therapy, spiritual therapy, heat and cold therapy, electrotherapy, cognitive behavioral
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therapy, exercise, physical therapy, and epidural and steroid injections (Denenberg &
Curtis, 2016; Gregory, 2014; Hooten et al., 2013; Rosenberg, 2013).

Naloxone use
Naloxone is an opioid receptor antagonist with no potential for abuse, which
reverses the effects of opioids in cases of respiratory depression and decreased
consciousness during an overdose. Naloxone produces little detectable pharmacological
action without the presence of an opioid agonist (Coe & Walsh, 2016; Doe-Simkins et al.,
2014). Access to and the use of naloxone is an essential tool in prescription opioid overdose
prevention. Distribution of naloxone is a safe, feasible, and effective intervention in
community settings. Also, laypersons can safely administer intranasal naloxone after brief
training (Drainoni et al., 2016). Distribution of naloxone to individuals who may witness
an overdose through community-based naloxone and overdose education programs have
shown a reduction in overdose deaths in these communities (Jones et al., 2016).
Recent legislative changes in several states have however allowed naloxone to be
administered by first responders, law enforcement officers, healthcare providers, family
members, and friends, as well as bystanders to an opioid, overdosed individual (Abuse,
2018; Coe & Walsh, 2016). Naloxone could also be dispensed to patients with a history of
overdose, substance abuse disorder, or those prescribed opioid medications (Abuse, 2016;
Currow et al., 2016).
Community-based distribution of naloxone in combination with proper prescription
opioid therapy decreases prescription overdose risk and mortality (Walley et al., 2013).
Many states now have "Standing Orders" (agreements with pharmacies and hospitals to
dispense naloxone to patients without a prescription) (Drainoni et al., 2016).
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Project Lazarus, a community-based overdose prevention program in Wilkes
County North Carolina, has recorded a 50% reduction in opioid-related deaths since its
inception. The program engages local prescribers, pain patients, and various non-medical
prescription opioid users to reduce opioid abuse and overdose. The program advocates and
offers naloxone as part of routine medical care to suspected prescription opioid abusers and
pain patients who are at high risk for overdose (Coe & Walsh, 2016; Doe-Simkins et al.,
2014).
Naloxone dispensing is recommended for individuals such as patients who have
been recently prescribed or treated with prescription opioids, suspected or confirmed
history of non-medical opioid use, or patients with a high dose of opioid prescription (doses
=100 MME) (Coe & Walsh., 2016). It is also recommended for opioid naïve patients who
have prescribed methadone, patients just recently released from prison, or mandatory
abstinence drug detox/program. Also, patients who have respiratory issues or disease (e.g.
asthma, COPD, emphysema, sleep apnea, smoker) are prescribed opioids (Coe & Walsh,
2016; Doe-Simkins et al., 2014). Naloxone could also be dispensed to patients with a
history of alcohol or harmful substance abuse, abuse of benzodiazepines, psychiatric
disorders, or cognitive impairments who are prescribed opioids (Coe & Walsh, 2016).
From 2013 to 2015, naloxone prescriptions dispensed in the United States has
increased more than ten (10) times. The same period notes a 187% increase in naloxone kit
distributed by community-based organizations, which have resulted in a 160% increase in
opioid overdose reversals (Jones et al., 2016).
Meanwhile, the significant adverse effect of naloxone in opioid-dependent patients
is the occurrence of withdrawal symptoms after administration due to the rapid
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displacement of opioid agonists from the opioid receptors. However, naloxone has no
abuse potential or psychoactive properties when used for long-term (Mueller et al., 2015).
The potential issue of stigma and mistrust that may surround naloxone prescribing
can be avoided by educating patients on the risk of respiratory depression from prescription
opioid use. The notion that prescription opioid abusers see naloxone as a “safety net,” and
hence increase opioid abuse, risky behaviors, and delay entry into addiction treatment is
false and has no scientific evidence (Coe & Walsh, 2016; Doe-Simkins et al., 2014).

Prescription Drug Monitoring Programs
Prescription Drug Monitoring Programs (PDMPs) are intended to detect and reduce
abuse, misuse, and diversion of controlled substances to reduce associated harm as well as
provide necessary information to enable healthcare providers offer appropriate medical
care (Paulozzi et al., 2012; Islam & McRae 2014).
The PDMPs also collect information on the individual patient's such age, gender,
payment method (e.g. insurance or cash), and the dispensing facility. They also give
information on the rate of prescribing and dispensing by both prescribers and pharmacies,
and on individuals receiving a combination of controlled substances such as opioids and
benzodiazepines. Data from the PDMP can help identify patients at risk of addiction as
well as those who might be diverting controlled substances. Such individuals tend to shop
from multiple providers and obtain controlled substances from different pharmacies in a
relatively short period. Research shows that effective PDMP increases clinicians’
confidence in opioid prescribing, help identify and reduce doctor shopping, and monitor
patients involved in opioid dependency treatment (Coplan et al., 2016).
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The effectiveness of PDMP could be assessed by monitoring the system and its
interoperability with other state programs such as addiction treatment centers (Coplan et
al., 2016). In a survey conducted by Liebling et al. (2016), out of 200 participants, about
42% of people who misuse or abuse prescription opioids are classified as self-treaters
whose main objective is to relieve pain. The survey also found that 24% of the participants
use prescription opioids for recreational purposes, whiles 34% are mixed users (selftreaters and recreational users). Research shows that recreational and mixed users are more
likely to be alcohol and illicit drug abusers (Coplan et al., 2016). Due to the interaction
between opioids and certain psychiatric medications such as benzodiazepines, barbiturates,
and other antidepressants, psychiatric patients are at increased risk of opioid overdose.
PDMPs ensure the appropriate use of controlled substances and detect diversion of
controlled substances. The information on demographic and geographical locations of
potential abusers enables public health providers to effectively implement intervention
programs (Brady et al., 2016).
Studies show that Florida had more than 80% increases in prescription drug
overdose deaths from 2003 to 2009 due to the abundance of pill mills. This was primarily
caused by doctor offices, clinics, or pharmacies, which prescribe and dispense controlled
medications to individuals with no legitimate medical purpose (Rutkow et al., 2015;
Delcher et al., 2015).
In Florida, the acquisition and distribution of opioid prescriptions, regarding MME
dropped by approximately 36% during the same period. It is also reported that the rate of
oxycodone diversion in Florida declined by 29% in the quarter after PDMP
implementation. From 2010 to 2012, oxycodone prescribing declined by 52.1%, and
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oxycodone-caused mortality decreased by 25% within the same period (Delcher et al.,
2015).
Definitions
Addiction
•

It is a chronic disease of brain reward, motivation, and memory circuitry, which is
characterized by a person’s inability to abstain consistently, impaired behavior
control, craving, and a dysfunctional emotional response (Lin, 2013).

Doctor shopper
•

This is when a patient seeks prescriptions from multiple providers without revealing
to each prescriber that other sources are involved. Individuals visiting more than
one provider and pharmacy for opioids during a specified period provide the basis
for this characterization. For example, an individual who uses more than five
prescribers for the same schedule of opioids in one calendar year is referred to as a
doctor shopper (Wilsey et al., 2013).

Drug misuse
•

This is the use of a drug for purposes for which it was not intended or using a drug
in excessive quantities. It is the use of controlled drugs with higher doses, or for a
more extended period than prescribed or the use of a prescription for a reason other
than the condition for which they were prescribed (Wise & Koob, 2014).

Opioid addiction
•

It is the powerful, compulsive urge to use opioid drugs even when they are no longer
required medically (Wise & Koob, 2014).

Opioid dependence
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•

This occurs when people consume opioids over a long period and develop physical
and psychological withdrawal symptoms such as muscle cramping, diarrhoea, and
anxiety (Wise & Koob, 2014).

Opioid overdose
•

This happens when there are so many opioids or a combination of opioids and other
drugs in the body that the victim is not responsive to stimulation, and breathing is
inadequate (Harm Reduction Coalition, 2018).

Unintentional poisoning
•

This involves the use of drugs or chemicals for recreational purposes in excessive
amounts.

Standing Order
•

This is a written document formulated collectively by the professional members of
a department or healthcare facility that could contain rules, policies, procedure,
regulations, or prescription orders for patient care (Lin, 2013).

Assumptions
The study assumes that strict and accurate application of the state-sponsored PDMP
regulations, as well as the availability of affordable and easily accessible naloxone by
patients at risk or their relatives, would result in a decrease in prescription opioid abuse
and overdose. This assumption is because the state reports on prescription opioid addiction
treatment and admissions decreased with the implementation of state-sponsored PDMPs
and the availability of naloxone in many states.
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Scope and Delimitations
Research shows that healthcare providers often lack the confidence to safely
prescribe opioid prescriptions or the ability to detect potential prescription opioid misuse
or abuse. They also lack the initiative or expertise to discuss the topic and consequences of
prescription opioid misuse or abuse with patients. Even though healthcare providers
acknowledge the use of prescription opioids to relieve moderate to severe pain, they have
a more significant concern about opioid abuse or addiction (Hwang et al., 2015).
Some prescribers are reluctant to prescribe controlled substances due to fear of the
legal repercussions. This results in the prescribing of alternative medications with less
effectiveness or more significant side effects. There is however a lack of uniformity and
knowledge in the use of opioid prescribing guidelines, as well as risk assessment tools to
prevent prescription opioid abuse. More so, the requirements to register and access the
PDMP information appears cumbersome to some healthcare providers, and interpretation
of the information hinders progress in their work (Ringwalt et al., 2014; Rosenberg, 2013;
Islam & McRae, 2014). In general, healthcare providers also lack experience and exposure
to opioid-related events and thus fear regulators and law enforcement breathing down their
necks (Abuse, 2018). There is the need to update guidelines across the state regularly and
nationwide, and to further compare guidelines across neighboring states for uniformity
(Abuse, 2018).
Patients fear the scrutiny from law enforcement if they use medications monitored
by the PDMP. They might also worry about the additional cost of required monthly visits
to the physician's office since such controlled drugs cannot be refilled without office visits.
The monitoring system of PDMPs is seen as a breach of patient-physician confidentiality
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or privacy. The public also views PDMP as a law enforcement tool rather than assisting in
safe therapy management. It therefore involves additional time and puts pressure on the
prescribers (Islam & McRae, 2014).
Research shows that young adults aged 18 to 25 use prescription opioids nonmedically and are unwilling to seek treatment due to lack of trust and stigmatization.
Additionally, healthcare professionals who happen to use prescription opioids nonmedically refuse to seek treatment due to perceived discrimination and stigmatization.
Other barriers include those inherent in the healthcare system such as treatment structure,
waiting times, payment methods, and confidentiality (Liebling et al., 2016).
Significance, Summary, and Conclusions
Life expectancy in the U.S.A is affected by the high rates of mortality in people
under 50 years of age who are dying due to unintentional drug overdose (Green et al.,
2015). PDMPs help healthcare providers to identify potential abusers, doctor shoppers in
different states and help to educate people on the need to use opioid prescribing guidelines
to reduce opioid misuse (Reisman et al., 2009; Li et al., 2014). Currently, there have been
about 644 community-based naloxone distribution programs in the U.S.A, with an estimate
of over 27,000 overdose reversals annually (Green et al., 2015).
Research shows that emergency department visits involving misuse or abuse of
prescription opioids have increased by 153% between 2004 and 2011 (Compton et al.,
2016). Community-based programs in States such as New Mexico, Massachusetts, and
New York have implemented successful naloxone distribution and overdose prevention
programs for at-risk patients, family members, and bystanders (Green et al., 2015).
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Research shows that community-based programs could result in about 74 % conﬁrmed
opioid overdose reversals (Rutkow et al., 2015).
Furthermore, there are currently many legislative changes in different states to
increase naloxone access to those at risk of opioid overdose. Many states have also passed
laws and issued standing orders that allow prescribers and pharmacists to prescribe and
dispense naloxone to people other than the person at risk of overdose such as friends and
family members of those at high overdose risk (Green et al., 2015).
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Section 2: Research Design and Data Collection
Introduction
Opioid drug misuse and dependence is a major social and public health problem
in the United States that has reached epidemic levels in the past few decades (Rudd et al.,
2016). Indeed, about 2 million U.S. adults abused or were addicted to prescription
opioids in 2014 (Hedden, 2015). Researchers have found that at least one in every four
people who have received prescription opioids for pain not related to cancer become
addicted at some point (Boscarino et al., 2015). Almost 50% of all deaths related to
opioid misuse involve a prescription opioid (Kolodny et al., 2015).
It is clear that dependence on opioids inflicts enormous social and economic costs
as a result of lost productivity, breakdown in relationships, healthcare costs, and expenses
related to law enforcement. Prescription opioid misuse and dependence cost the U.S.
economy a projected $78.5 billion (Florence et al., 2016).
In this study, data from 2014 to 2018 in Florida and in Georgia were compared
and analyzed separately to assess the effect of state-sponsored PDMPs as well as the
impact of naloxone standing orders and the availability of naloxone to at-risk patients or
their relatives without prescription.
Research Design and Rationale
The study relied on using secondary data to determine the association between the
implementation of state-sponsored PDMPs and prescription opioid abuse/overdose as
well as the effect of state-issued standing orders to make naloxone readily available to
people at risk.
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An observational study was however the appropriate study design for this study.
Observational studies can be used to study the effects of a broader range of exposures and
diseases in the population to draw inferences on the prevention, treatment, and possible
causes of the disease. This type of study also helps to provide information to explain the
causes of disease incidence and the determinants of disease progression to predict the
future healthcare needs of the population and to control diseases by studying ways to
prevent them as well as prolong the lives of those who have the disease. The two main
subtypes of observational study are descriptive and analytic studies (Aschengrau &
Seage, 2014; Omair, 2015; Thiese, 2014).
The study also adopted the ecologic research design approach, which is an
observational analytic study. In an ecological study, the unit of analysis is the group. The
rate of exposure or exposed person and the rate of disease or the number of cases is
known. However, the number of exposed cases is unknown. This study involves an
assessment of the association between exposure rate (which is the availability of
prescription opioids through written or dispensed prescriptions) and disease rate (which is
the use/abuse and overdose) among different age groups and gender. This also includes
finding out the incidence rates, prevalence rates, and mortality rates of the disease
(Aschengrau & Seage, 2014; Omair, 2015; Thiese, 2014).
Ecologic studies are quick, simple to conduct, and inexpensive. However, the
level of exposure of each individual in the unit being studied is not known. Besides, the
overall ecologic trend or the correlational changes in the exposure and disease are
reviewed.
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The use of a quasi-experimental design was inappropriate for this study since it
only gives information on whether the implementation or introduction of a public health
program or policy was successful or failed. It also involves the manipulation of the study
factors but not the randomization of the study subjects. Thus, it only evaluates the extent
to which a program meets their public health goals (Aschengrau & Seage, 2014; Omair,
2015; Thiese, 2014).
The establishment of PDMPs through various state legislations and the granting
of standing orders to dispense naloxone to at-risk patients have tremendously affected the
abuse/overdose of prescription opioids. PDMPs and naloxone distribution have
contributed to the slow down or curtailing of the opioid epidemic in the U.S. Many states
now have laws that require providers and pharmacists to record any controlled substance
prescription written or dispense within 24 hours of issuance. This allows current data to
be accessed in the shortest possible time to determine the current trend of prescription
opioid abuse/overdose. The data would also include the number of trained personnel who
may use the PDMP program, such as licensed prescribers (which include optometrists,
physicians, nurse practitioners, physician assistants, dentists, pharmacists, and law
enforcement officers).
Methodology
This study adopted a quantitative research approach where existing data from
various state health departments were collated and analyzed. The data included the
annual reports for the last 5 years from the states PDMPs and drug overdose mortalities.
Emails were sent to the various state’s public health departments for quarterly and annual
data on prescription opioid use and overdose, particularly from Florida and Georgia.
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The Target Population
The population target is all patients in the states of Florida and Georgia who have
prescribed opioid prescriptions in the past 5 years. The data includes personal data (i.e.,
age and gender) but not the patients’ names, addresses, or any identifiable data to link a
person’s identity to this study.
The Sample Frame
The sample frame is all controlled substance prescriptions recorded in the states’
PDMP data between the years 2014 and 2018 in Florida and Georgia. The PDMP collates
all the controlled substance prescription data from both healthcare providers and
pharmacies.
Sampling and Sampling Procedures
The sampling process for this study was done by using convenient sampling.
Convenience sampling is a non-probability sampling technique where subjects are
selected because of their convenient accessibility and proximity to the researcher. Data
was therefore obtained from the PDMP annual reports from the department of health
websites for the states of Florida and Georgia because that was the most convenient
source of the data needed.
Data from the National Survey on Drug Use and Health (NSDUH) from the
SAMSHA website with regard to Florida and Georgia were also collected. The NSDUH
is a nationwide survey of civilian non-institutionalized population aged 12 years and
older in the United States of America. The survey excludes individuals with no fixed
household address, active-duty military personnel, and residents of institutional groups.
The data collection method used by NSDUH included in-person interviews. Sampled
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individuals were asked their willingness to report honestly about sensitive topics such as
illicit drug use behavior and mental health issues. Confidentiality was emphasized in all
written and oral communications with each respondent and their identities were
protected. This was also ensured in cases where private interviews were performed using
computer-assisted interviewing methods where researchers read questions from a
computer or laptop and entered the responses.
Sample Size
The number of people interviewed in Florida in 2013 was 3,600 and in Georgia
was 900. The number of people interviewed between 2014 and 2018 was 3,300 in Florida
and 1,500 in Georgia. The selected age groups were 18-25, 26-34, 35-49, 50-64, and 65
or older, respectively. The sample was also made up of Hispanic, White, and Black
respondents. The gender was male or female. Even though the NSDUH survey involved
multiple questions on drug use and mental health, this study focused only on the opioid
prescription data, which included hydrocodone, oxycodone, tramadol, codeine, morphine,
fentanyl, hydromorphine, oxymorphine products, and methadone.
Instrumentation and Operationalization
Data from 2014 to 2018 provided by the PDMP program in Florida and Georgia
were gathered. This was done by contacting the Electronic-Florida Online Reporting of
Controlled Substance Evaluation (E-FORCSE) agency responsible for the state PDMP
program in Florida and Georgia, the Epidemiology Section of the Department of Public
Health accountable for the state PDMP program. The PDMPs collect prescription
information on all controlled substances in the state. The DEA has five schedules for
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controlled substances. The classification is based on the medication’s potential for abuse,
if it is accepted as a medical treatment, and the safety of its use, as follows:
•

Schedule 1 drugs have the highest potential for abuse, but currently have no
medical use and no safety use. Examples include heroin and cocaine.

•

Schedule II drugs have a high potential for abuse and have current medical
use but may lead to severe physical and psychological dependence. Examples
include Oxycodone, Hydrocodone, and Ritalin.

•

Schedule III drugs have the potential for abuse; they have medical use but
may lead to moderate physical and psychological dependence. Examples
include steroids and some codeine products.

•

Schedule IV drugs have a low potential for abuse; they have medical use but
may lead to limited physical and psychological dependence. Examples are
Xanax, Ambien, and Tramadol.

•

Schedule V drugs have a low potential for abuse; they have medical use but
may lead to limited physical and psychological dependence. Examples are
Lyrica and Lomotil.

In this study, I gathered data mainly on schedule II prescription opioids. The data
contained the gender and age of the patients. However, all the personal identities of the
patients were excluded. The age groups considered were adults 25 to 64 years. The data
was coded and entered using the IBM SPSS version 25.0 (IBM, 2017). I conducted
descriptive, inferential analysis of variance and multiple linear regressions of the
variables in the research questions using the SPSS software.
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Research Questions and Hypotheses
RQ1: Is there an association between the number of state-sponsored PDMPs
trained health care providers per year and the number of reported opioid overdoses per
year among adults 25 to 64 years?
H01: There is no association between the number of state-sponsored PDMPs
trained healthcare providers per year and the number of reported opioid overdoses
per year among adults 25 to 64 years.
H11: There is an association between the number of state-sponsored PDMPs
trained healthcare providers per year and the number of reported opioid overdoses
per year among adults 25 to 64 years.
RQ2: Is there an association between the number of state-sponsored PDMPs
trained healthcare providers and the number of opioid addiction treatment admissions per
year among adults 25 to 64 years?
H02: There is no association between the number of state-sponsored PDMPs and
the number of opioid addiction treatment admissions per year among adults 25 to
64 years.
H12: There is an association between the number of state-sponsored PDMPs
trained physicians and the number of opioid addiction treatment admissions per
year among adults 25 to 64 years.
RQ3: Is there an association between the number of state-sponsored PDMPs
trained healthcare providers and the number of deaths attributed to opioid overdoserelated deaths per year among adults 25 to 64 years?
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H03: There is no association between the number of state-sponsored PDMPs
trained healthcare providers per year and the number of opioid over dose-related
deaths per year among adults 25 to 64 years.
H13: There is an association between the number of state-sponsored PDMPs
trained healthcare providers and the number of deaths attributed to opioid
overdose-related deaths per year among adults 25 to 64 years.
RQ4: Is there an association between community-based naloxone distribution and
the number of reported opioid overdoses per year among adults 25 to 64 years?
H04: There no association between community-based naloxone distribution and
the number of reported opioid overdoses per year among adults 25 to 64 years.
H14: There is an association between community-based naloxone distribution and
the number of reported opioid overdose per year among adults 25 to 64 years.
RQ 5: Is there an association between community-based naloxone distribution and
the number of opioid addiction treatment admissions per year among adults 25 to 64
years?
H05: There is no association between community-based naloxone distribution and
the number of opioid addiction treatment admissions per year among adults 25 to
64 years.
H15: There is an association between community-based naloxone distribution and
the number of opioid addiction treatment admissions per year among adults 25 to
64 years.
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RQ6: Is there an association between community-based naloxone distribution and
the number of deaths attributed to opioid misuse/overdose per year among adults 25 to 64
years?
H06: There is no association between community-based naloxone distribution and
the number of deaths attributed to opioid misuse/overdose per year among adults
25 to 64 years.
H16: There is an association between community-based naloxone distribution and
the number of deaths attributed to opioid misuse/overdose per year among adults
25 to 64 years.
Data Analysis Plan
Independent Variables
The independent variables include the number of state-sponsored PDMP trained
healthcare providers, the number of naloxone community-based distribution center opioid
prescriptions written and dispensed, the number of naloxone community-based
distribution center opioid prescriptions with MME above 90, and the number of naloxone
community-based distribution center opioid naïve patients (patients who have never used
prescription opioids or have not used prescription opioids in 6 months or more).
Dependent Variables
The dependent variables include the number of reported opioid overdoses per year
among adults 25 to 64 years, the number of opioid addiction treatment admissions per
year, and the number of opioid-related deaths per year among adults 25 to 64 years.
Controlling variables include the age group and gender of the patients.
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Table 2
Research Questions, Dependent Variables, and Independent Variables and Level of
Measurement
Research questions

Independent variables

RQ 1: Is there an association between The number of PDMP
the number of state-sponsored PDMPs trained healthcare providers
trained healthcare providers per year per year/ Continuous
and the number of reported opioid
overdoses per year among adults 25 to
64 years?
RQ 2: Is there an association between The number of PDMP
the number of state-sponsored PDMPs trained healthcare providers
trained healthcare providers and the per year/ Continuous
number of opioid addiction treatment
admissions per year among adults 25 to
64 years?
RQ 3: Is there an association between
the number of state-sponsored PDMPs
trained healthcare providers and the
number of deaths attributed to opioid
overdose-related deaths per year among
adults 25 to 64 years?
RQ 4: Is there an association between
community-based naloxone distribution
and the number of reported opioid
overdoses per year among adults 25 to
64 years?

The number of statesponsored PDMPs trained
healthcare providers per
year/ Continuous

RQ5: Is there an association between
community-based naloxone distribution
and the number of opioid addiction
treatment admissions per year among
adults 25 to 64years?

Community-based naloxone
distribution (the number of
opioid prescriptions with
MME higher than 90mg)/
Continuous

Community-based naloxone
distribution (the number of
opioid prescriptions written
and dispensed) per year/
Continuous

RQ 6: Is there an association between Community-based naloxone
community-based naloxone distribution distribution (The number of
and the number of deaths attributed to opioid naïve patients)/
Continuous

Dependent
variables
The number of
reported
opioid
overdoses per
year/
Continuous
Number of
opioid
addiction
treatment
admissions per
year/
Continuous
The number of
opioidoverdoserelated deaths
per
year/
Continuous
The number of
reported
opioid
overdoses per
year/
Continuous
The number of
opioid
addiction
treatment
admissions per
year/
Continuous
The number of
opioid-related
deaths
per
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opioid misuse/overdose per year among
adults 25 to 64 years?

year/
Continuous

The manipulation of the data was done using IBM’s Statistical Package for Social
Sciences. The research adopted descriptive statistics as one of its tools of analysis.
Descriptive statistics describe the relationship between variables in a sample or population.
Inferential statistics was also adopted to make inferences about the whole population as
well as to measure the central tendencies to describe the rate of prevalence. The study also
used the Analysis of Variance to assess if there is a significant difference between the
variables. This was to help evaluate whether or not there is a between-group variability or
within-group variability (error variance). The within-group variability is based on the
random differences within the population.
Multiple regressions were also run with SPSS to find out whether or not there is a
linear relationship between the dependent and independent variables, the presence of
homogeneity, absence of outliers, standard distribution errors, as well as single variant and
multivariate normality.
Non-parametric test is used when the assumption of normality is not met, and the sample
means are not normally distributed. It is sometimes referred to as distribution-free tests.
Parametric test involves specific probability distributions (e.g., the normal distribution)
and the tests involve estimation of the key parameters of that distribution (e.g., the mean
or difference in means) from the sample data.
However, non-parametric tests may fail to detect a significant difference when
compared to parametric analysis. The non-parametric test used in this study was the MannWhitney test. It is used to test the null hypothesis when two samples have the same median
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or whether observations in one sample tend to be larger than observations in the other. The
study also used the Kruskal-Wallis test to analyze the variance between the research
variables. It analyses if there is any difference in the median values of three or more
independent samples. The data values were ranked in increasing order, and the rank sums
were calculated.
Threats to Validity and Reliability
Validity is the extent to which a concept is accurately measured in a quantitative
study. There are three major types of validity: Content validity, Construct validity and
Criterion Validity. Content validity is the extent to which a research instrument accurately
measures all aspects of a construct. Construct validity is the extent to which a research
instrument measures the intended construct. Criterion validity is the extent to which a
research instrument is related to other instruments that measure the same variables (Heale
& Twyross, 2015).
Internal validity relates to participants selection, data recording and data analysis
of the data, while external validity refers to the generalizability of the study and whether it
can be transferred to other populations (Lakshimi & Mohideen, 2013).
According to Drost (2011), internal validity refers to the validity of the study, as to
whether there is a strong or causal relationship between the variables and the effects of any
confounding factors. There are at least 12 threats to the internal validity of a study. These
include history, maturation, testing, instrumentation, statistical regression, differential
selection, experimental mortality, selection-maturation interaction, experimental treatment
diffusion, compensatory equalization, rivalry, and demoralization.
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On the other hand, external validity refers to the generalizability of the research
findings. Some of the threats of external validity include:
•

The extent to which one can generalize from the experimental sample to a
defined population.

•

The extent to which phonological variables interact with treatment
variables.

•

Explicit description of the experimental treatment and the Hawthorne effect

•

Multiple-treatment interference

•

Interaction of history and treatment effects.

•

Measurement of the dependent variables and

•

Interaction of time measurement and treatment effects.

According to Koziol and Arthur (2011), studies sponsored by the government
generally involve larger samples that are more representative of the target population due
to the availability of adequate funds, material, and human resources. State-sponsored
agencies compiled the PDMP data with all the necessary elements. Due to this, the dataset
had numerous variables; therefore, there was increased and strong statistical precision.

Reliability
The reliability and validity of research depend on the instruments used by the
researchers to gather data. According to Drost (2011), reliability is the extent to which
measurements are repeatable when different persons perform the analyses on various
occasions under different conditions with alternative instruments that measure the same
thing.
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There are three types of reliability: test-retest reliability, inter-rater reliability and
internal consistency reliability. Test-retest reliability evaluates the stability of measures
administered at different times using the same individuals or the same standards. Inter-rater
reliability establishes the equivalence of ratings obtained with an instrument when used by
different observers. Reliable measurement will require consistency between different
raters, and there should be no collaboration between raters. Inter-rater Reliability is
determined by the coefficient of agreement of the judgment of the raters or Cohen's kappa.
Internal consistency reliability gives an estimate of the equivalence of sets of items from
the same test. The Coefficient of internal consistency or Cronbach's alpha is a function of
the average inters correlations of items and the number of items in the scale. Its value is
expressed from 0 to 1 (Drost, 2011; Lakshmi & Mohideen, 2013).
Most government and state-sponsored research have a Cronbach's alpha of at least
0.9. This study's data is extracted from reliable state data which is used in government
policymaking. The validity and reliability of the data can be guaranteed since the
population size is vast, and the data is also used for budgeting purposes. Thus, its accuracy
can be assured.
Ethical Procedures
All the data collected are readily available to the public on the state's health
department websites. The IRB requirement was to take the CITI program course for student
researchers which was completed on Jan 9, 2019, and the NIH web-based training course
for Protecting Human Research Participants, which was also completed on July 3, 2016.
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Summary
In this section, the study sought to compare the retrospective secondary data using
observational ecologic study. The ecologic research design considers the rate of exposure
or exposed person and the rate of disease or the number of cases known. This study
involves an assessment of the correlation between exposure rate (the availability of
prescription opioids through written or dispensed prescriptions) and disease rate (the
number of cases that use/abuse and/or overdose) by age group and gender. The data was
taken from both national surveys by the NSDUH from SAMSHA and the websites of the
state Department of Health in Florida and Georgia.
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Section 3: Presentation of the Results and Findings
Introduction
The purpose of this chapter is to present the findings and analyses of the effects of
state-sponsored PDMPs, trained healthcare providers, and community-based naloxone
distribution in Florida and Georgia on the prevention and reduction of prescription opioid
abuse and overdose. Prescription drug abuse and overdose are associated with substantial
morbidity and mortality rates, as well as social and economic costs.
In this chapter, the variables explored were: the number of opioid prescriptions
written in each year, the number of opioid prescriptions with MME above 90 per year,
the number of opioid-naive patients (i.e. patients who have never used opioid
prescriptions or have not used in the last 6 calendar months), the number of healthcare
providers trained to use the PDMP in each year, the number of opioid-related emergency
room visits and admissions each year, the number of opioid-related admissions into
treatment centers each year, the number of opioid-related deaths each year, and the age
and gender of the patients.
Data Collection and Analyses
The data for this study were collected from the Department of Public Health
websites for both the State of Florida and Georgia from the years 2014 to 2018.
The research questions and hypotheses for the study are as follows:
RQ1: Is there an association between the number of state-sponsored PDMPs
trained healthcare providers per year and the number of reported opioid overdoses per
year among adults 25 to 64 years?
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H01: There is no association between the number of state-sponsored PDMPs
trained healthcare providers per year and the number of reported opioid overdoses
per year among adults 25 to 64 years.
H11: There is an association between the number of state-sponsored PDMPs
trained healthcare providers per year and the number of reported opioid overdoses
per year among adults 25 to 64 years.
RQ2: Is there an association between the number of state-sponsored PDMPs
trained healthcare providers and the number of opioid addiction treatment admissions per
year among adults 25 to 64 years?
H02: There is no association between the number of state-sponsored PDMPs and
the number of opioid addiction treatment admissions per year among adults 25 to
64 years.
H12: There is an association between the number of state-sponsored PDMPs
trained physicians and the number of opioid addiction treatment admissions per
year among adults 25 to 64 years.
RQ3: Is there an association between the number of state-sponsored PDMPs
trained healthcare providers and the number of deaths attributed to opioid overdoserelated deaths per year among adults 25 to 64 years?
H03: There is no association between the number of state-sponsored PDMPs
trained healthcare providers per year and the number of opioid overdose-related
deaths per year among adults 25 to 64 years.
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H13: There is an association between the number of state-sponsored PDMPs
trained healthcare providers and the number of deaths attributed to opioid
overdose-related deaths per year among adults 25 to 64 years.
RQ4: Is there an association between community-based naloxone distribution and
the number of reported opioid overdoses per year among adults 25 to 64 years?
H04: There no association between community-based naloxone distribution and
the number of reported opioid overdoses per year among adults 25 to 64 years.
H14: There is an association between community-based naloxone distribution and
the number of reported opioid overdose per year among adults 25 to 64 years.
RQ 5: Is there an association between community-based naloxone distribution and
the number of opioid addiction treatment admissions per year among adults 25 to 64
years?
H05: There is no association between community-based naloxone distribution and
the number of opioid addiction treatment admissions per year among adults 25 to
64 years.
H15: There is an association between community-based naloxone distribution and
the number of opioid addiction treatment admissions per year among adults 25 to
64 years.
RQ6: Is there an association between community-based naloxone distribution and
the number of deaths attributed to opioid misuse/overdose per year among adults 25 to 64
years?
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H06: There is no association between community-based naloxone distribution and
the number of deaths attributed to opioid misuse/overdose per year among adults
25 to 64 years.
H16: There is an association between community-based naloxone distribution and
the number of deaths attributed to opioid misuse/overdose per year among adults
25 to 64 years.
Descriptive Demographics and Univariate Analysis of the Florida Sample
Data were collected from the Florida State Health Department’s PDMP
(Electronic-Florida Online Reporting of Controlled Substances Evaluation- E-FORSCE)
website from the years 2014 to 2018. The variables were the total number of prescription
opioid written per year from 2014 to 2018, the total number of yearly prescriptions with
MME greater than 90mg (MME>90), the total number of yearly emergency room
admissions and visits, the total number of healthcare providers trained per year, the total
number of opioid naïve patients, and the number of prescription opioid written with daily
MME > 90mg. The results are shown in Table 3.
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Table 3
Florida PDMP Data
Year
Number of
opioid RXs

2014
15,588,677

2015
16,789,300

2016
16,809,626

2017
16,221,421

2018
15,402,14
1

Total MME
per opioid
RXs
Number of
ER visits &
admissions

661

657

609.6

624.6

643.4

12,787

11,263

13,285

16,138

11,820

14,029

46,992

34,290

27,621

41,217

7,520,189

6,917678

6,574,384

6,415,235

6,311,743

282,980

277,698

206,088

194,561

186,821

Number of
providers
trained in
PDMP
Number of
opioid naïve
patients
Number of
RX with daily
MME>90

Opioid rate per patient’s age range
25-34

1,200

1,100

1,200

1,250

1,300

34-44

1,600

1,600

1,500

1,550

1,500

45-54

2,150

2,200

2,300

2,250

2,050

55-64

2,600

3,000

2,800

2,750

2,600

Opioid RX for male & female (ages 25-64)
Females

4,030,000

4,200,000

4,300,000

4,350,000

4,250,000

Males

3,500,000

3,600,000

3,700,000

3,850,000

3,750,000

50

Opioid deaths age range
25-34

486

733

1031

967

1218

35-50

959

1486

1831

1733

1651

Above 50

1583

2140

2426

2463

2394

Explanation and Comparison of Variables-Florida
Total Number of Opioid Prescriptions
The total number of yearly opioid prescriptions peaked in 2016 and began to
decline as shown in Figure 2.
Figure 2
Total Number of Yearly Prescriptions From 2014 to 2018, Florida
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The Total Number of Morphine Milligram Equivalents (MME) per Opioid
Prescription
The total number of MME per opioid prescription has been increasing gradually,
which in turn increases the addictiveness of the opioid medication, as shown in Figure 3.
Figure 3
Total Morphine Milligram Equivalents (MME) per Opioid Prescription

Total MME per opioid rxs
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The Total Number of Emergency Room (ER) Visits and Admissions
The number of opioid-related ER visits and admissions increased from 2015 to
2017; however, the number began to decrease in 2018, as shown in Figure 4.
Figure 4
Total Number of Yearly ER Visits and Admissions From 2014 to 2018

Number of ER visits & admissions
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The Total Number of Opioid-Related Deaths
The number of opioid-related deaths almost doubled from 2,538 in 2015 to 4,280
in 2017. This is represented in Figure 5
Figure 5
Number of Yearly Opioid-Related Deaths from 2014 to 2018

Number of opioid related deaths
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The Number of Healthcare Providers Trained in PDMP
The year 2015 had the highest number of trained healthcare providers, and there
was a decrease in the following 2 years. However, the numbers went back up in 2018, as
shown in Figure 6.
Figure 6
Number of Healthcare Providers Trained in PDMP

Number of providers trained in PDMP
50,000

46,992

45,000

41,217

40,000
35,000

34,290

30,000

27,621
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10,000
5,000
0
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2015

Figure 7
Number of Opioid Naïve Patients
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Opioid Naïve Patients
7,800,000
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Figure 8
Number of Prescriptions with Daily MME>90
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Opioid rate per patient age group
The opioid rate per 1,000 patient age group remained steady over the years, with
the 55 64 age groups being the highest consumers as shown in Figure 3.8.
Figure 9
Opioid rate per patient age group

OPIOID PER PATEINT BY AGE
RANGE
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Total Number of Opioid prescription for Male and Female
The result shows that females consume more opioid prescriptions than males over the
years.
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Figure 10
Number of yearly opioid prescriptions per gender

Opioid per gender ages 25-64
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4,030,000
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Years
Total Number of Opioid-related deaths by age group
The total number of opioid-related deaths are highest among people 50 and older over the
years from 2014 to 2017.
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Figure 11
Number of yearly opioid-related deaths by age group

OPIOID DEATH BY AGE RANGE
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Descriptive Demographics and Univariate Analysis of the Georgia Sample
The Georgia PDMP is also managed by the State’s Department of Health. The
available data collected were from the year 2014 to 2018. They include the total number of
prescription opioids written per year; the number of Emergency Room visits & admissions
from; the number of opioid-related deaths in the state; the number of opioid naïve patients
(thus patients who have not had any opioid prescriptions in past 6 months or more); and
the number of prescription opioids with a daily MME greater than 90.
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Table 4
Georgia PDMP Data
Year

2014

2015

2016

2017

2018

Number of Opioid

8,912,489

8,736,389

8,589,707

8,001,050

7,487,527

9,569

8,484

7,843

8,278

7,359

249,561

217,821

184,170

172,034

125,140

320,189

311,743

298,402

224,297

217,359

1,304

1,268

954

1,051

876

RX’s
Number of ER
visits &
admissions
Number of RX
with Daily
MME>90
Number of Opioid
Naïve Patients
Number of Opioid
Related Deaths
Opioid Rate Per Patient's Age
Range
25-34

781,171

681,132

600,542

751,408

651,423

34-44

1,677,522

1,491,238

899,000

1,110,468

991,575

45-54

1,740,394

1,639,475

1,225,000

1,568,651

1,409,081

55-64

1,760,198

1,569,760

1,650,000

1,404,320

1,879,290

Opioid Per Gender & Age (25-64 years)
Female

5,163,798

5,052,724

4,953,000

4,689,364

4,387,736
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Male

4,352,101

4,211,484

3,705,000

3,304,324

3,094,257

Opioid Deaths Age Range
25-34

288

255

231

303

220

35-44

264

259

279

307

225

45-54

299

295

298

305

171

55-64

178

165

189

198

135

Explanation and Comparison of Variables-Georgia
Total Number of Opioid Prescriptions
The total number of opioid prescriptions dispensed to patients has been decreasing from
2014 to 2018 as shown in Figure 3.11.
Figure 12
Total number of opioid prescriptions, Georgia
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Total Number of ER Visits and Admissions
The number of ER visits and admissions peaked in 2017; however, it relatively reduced
in 2018.
Figure 13
The number of Emergency Room visits and admissions, Georgia
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Total number of opioid-related deaths
The number of opioid-related deaths peaked in 2017 just as the number of ER visits
and admissions and began to decrease.
Figure 14
Number of opioid-related Deaths, Georgia
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Total Number of opioid naïve patients
The total number of opioid naïve patients decreased over the years from 2014 to 2018.
Figure 15
Number of opioid naïve patients

Opioid Naïve Patients
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Total Number of Opioid Prescriptions with daily MME>90
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The total number of prescriptions with daily MME>90 has been decreasing over the years
from 2014 to 2018.
Figure 16
Number of opioid prescriptions with daily MME>90
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Opioid rate per Patient Age Group
The rate of opioid consumption among age groups between 45 to 54 years and 55
to 64 is among the highest from 2014 to 2018.
Figure 17
Opioid rate per patient’s age groups
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Prescription Opioid Consumption between Male and Female Ages 25-64 years
The data shows that females consume more opioid prescriptions than males in all
the years compared as presented in Figure 3.17.
Figure 18
Opioid RX for male and female
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The total number of opioid deaths among age groups has been reducing over the
years from 2014 to 2018. Furthermore, the data also shows that the ages between 35-44
and 45-54 have the highest mortality rates.
Figure 19
Number of opioid-related deaths per age group

OPIOID DEATHS BY AGE GROUP
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Descriptive Statistics for Florida Data
The number of Trained Providers has a mean of 32829.80 (S.D 12783.26). The mean for
the number of yearly Opioid Prescriptions is 16,162,233.0 (S.D 656227.91). The mean for
Emergency Room Visits and Admissions per year is 13,058.6 (SD 1,895.13). The mean for
Opioid-Related Deaths per year is 3,767.2 (SD 734.97). The mean for the MME per year
is 638.52 (SD 22.82). The mean for Opioid Naïve Patients is 674,784.5 (SD 488,943.13).
The mean for Prescription with daily MME >90 is 229,629.6 (SD 46,833.28) (See: Table
3.3).
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Table 5
Descriptive Statistics for Florida

Year Prescriptions

Mean
16,162,233

Std Deviation
656,227.91

Std Error
293,474.04

Trained Providers

32,829.8

12,783.26

5,716.85

Emergency Room
visits

13,058.6

1,895.13

847.53

Opioid-Related
Deaths

3,767.2

734.97

328.69

MME per Opioid
RX’s

638.52

22.82

10.21

Opioid Naïve
patients

674,784.8

488,943.14

21,8662.02

RX Daily MME>90

229,629.6

46,833.28

20,944.48

To test the null hypothesis for the Research Questions 1 to 3 which states that there is no
association between the number of state-sponsored PDMPs trained healthcare providers
and the number of opioid overdoses, the number of opioid admissions and the number of
opioid-related deaths a one-way ANOVA (Analysis of Variance) was conducted using
SPSS software version 21 and post-hoc test using the Tukey HSD to evaluate pairwise
differences between means of the variables. The results from the ANOVA analysis
revealed a significant difference in the mean of trained providers with F (6, 28) =
1996.172127.68, p<.001.
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Table 6
One-way ANOVA for Florida Data
Source
Sum of Squares
Df
Mean Square
F
Sig
Between 1149900086613551.8 6
191650014435591.97 1996.172 .000
groups
Within
2688245461020.12
28
96008766465.01
groups
Total
1152588332074572.0 34
In accordance with the post-hoc tests, it is notable that there are significant
differences within the variables. There is a significant difference between the mean of the
number of trained providers and the mean of the number of yearly prescriptions (mean
difference=16,129,403.20) with 95% C.I (15,507,766.81, 16,751,039.59). There is a
significant difference between the mean of the number of yearly prescriptions and the mean
of the number of emergency room visits and admissions (mean difference=16,149,174.4)
with 95% C. I (15,527,538.0, 16,770,810.79).
There is a significant difference between the mean of the number of yearly
prescriptions and the mean of the number of opioid-related deaths (mean
difference=16,158,465.8)

with

95%

CI

(Confidence

Interval)

(15,536,829.4,

16,780,102.19). There is also a significant difference between the mean of the number of
yearly prescriptions and the mean of the number of prescriptions with MME>90) (mean
difference= 16,161,594.48) with 95% CI (15.539, 958.09, 16,783,230.87).
There is also a significant difference between the number of yearly prescription and
opioid naïve patients (mean difference=9,414,387.2) with 95% CI (8,792,750.81,
10,036,023.59). There is a significant difference between the number of yearly prescription
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and the number of prescription with Daily MME>90 (mean difference=15,932,603.4) with
95% CI (15,310,967.01, 16,554,239.79). There is a significant difference between the mean
of the number of trained providers and the mean of the number of emergency room visits
and admission (mean difference=19,771.2) with 955 CI (-601,865.19, 641,407).
There is a significant difference between the mean of the number of trained
providers

and

the

mean

of

the

number

of

opioid-related

deaths

(mean

difference=29,062.60) with 95% CI (-592573.79, 650,698.99). There is a significant
difference between the mean of the number of trained providers and the mean of the
number

of

prescriptions

with

Morphine

Milligram

Equivalence>90)

(mean

difference=32,191.28 with 95% C I (-589,445.11, 653,827).
There is a significant difference between the mean of the number of trained
providers and the mean number of opioid naïve patients (mean difference=6,715,016.00)
with 95% CI (7,336,652.39, -6,093,379.61). There is a significant difference between the
mean of the number of trained providers and the mean of the number of prescription with
Daily MME>90 (mean difference= 196,799.80) with 95% CI (-818,436.19, 424,836.59).
There is a significant difference between the mean of the number of emergency
room visits and admissions and the mean of the number of Opioid-related deaths (mean
difference=9,291.40) with 95% CI (-641,407.59, 601,865.19). There is a significant
difference between the mean of the number of emergency room visits and admissions and
the mean of the number of prescriptions with MME>90 (mean difference=12501.6) with
95% CI (-786869.6, 811872.9) (mean difference=12,420.08) with 95% CI (-609,216.31,
634,056.47). There is a significant difference between the mean of the number of
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emergency room visits and admissions and the mean of the number of opioid naïve patient
(mean difference= 6,734,787.20) with 95% C.I (-7,356,423.59, -6,122,442.21).
There is a significant difference between the mean of the number of emergency
room visits and admissions and the mean of the number of prescription with Daily MME>
90 (mean difference= 216571.00) with 95% CI (-838207.39, 405,065.39). There is a
significant difference between the mean of the number of Opioid-related Deaths and the
mean of the number of prescriptions with MME>90 (mean difference=3128.68) with 95%
CI (-618,507.71, 624,765.07).
There is a significant difference between the mean of the number of Opioid-related Deaths
and the mean of the number of opioid naïve patients (mean difference= 6,744,078.60 with
95% CI (-73,65,714.99, -6,122,442.21).
There is a significant difference between the mean of the number of Opioid-related
Deaths and the mean of the number of prescriptions with Daily MME > 90 (mean
difference=225,862.40) with 95% CI (-847,498.79, 395,773.99). There is a significant
difference between the means of the MME per Prescription and the mean of the number of
opioid naïve patients (mean difference=6,747,207.28) with 95% CI (-7,368,843.67, 5656759.7880). There is a significant difference between the means of the MME per
Prescription and the mean of the number of prescriptions with Daily MME>90 (mean
difference=22,899.80 with 95% CI (-850,627.47, 39,245.31). There is a significant
difference between the mean of the number of opioid naïve patients and the mean of the
number of prescriptions with daily MME >90 (mean difference= 6,518,216.20) with 95%
CI (5,896,579.81, 7,139,852.59). This is presented in Table 3.5 below.
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Table 7
Pairwise Differences in Mean and Corresponding 95% Confidence Intervals-Florida data
Trained
Providers
Yearly
16,129,403.20
Prescriptions (15,507,766.81,
16,751,039.59)

Emergency Room
visits
16,149,174.4
(15,527,538.0,
16,770,810.79)

Opioid-Related
Deaths
16,158,465.8
(15,536,829.4,
16,780,102.19

Trained
providers

19,771.2 (601,865.19,
641,407)

Emergency
Room Visits

OpioidRelated
Deaths
MME PER
Opioid RX
Opioid
Naïve
patients
RX Daily
MME>90
*. The mean difference is significant at the 0.05 level

Opioid Naïve
Patients
9,414,387.2
(8,792,750.81,
10,036,023.59)

RX Daily
MME>90
15,932,603.4
(15,310,967.01,
16,554,239.79)

29,062.60 (592573.79,
650,698.99)

MME per
Opioid RX
16,161,594.4
8
(15.539,958.0
9
16,783,230.8
7)
32,191.28 (589,445.11,
653,827)

-6,715,016.00
(7,336,652.39,
-6,093,379.61)

-196,799.80
(-818,436.19,
424,836.59)

9,291.40 (641,407.59,
601,865.19)

12,420.08 (609,216.31,
634,056.47)

-6,734,787.20
-216571.00 ((-7,356,423.59, 838207.39,
-6,122,442.21) 405,065.39)

3128.68 (618,507.71,
624,765.07)

-6,744,078.60
-225,862.40
(-73,65,714.99, (-847,498.79,
-6,122,442.21) 395,773.99
-6,747,207.28
-22,899.80
(-7,368,843.67, (-850,627.47,
-5656759.7880 39,245.31)
6,518,216.20
(5,896,579.81,
7,139,852.59)
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Descriptive Statistics for Georgia Data
The yearly prescription opioid has a mean of 8026094.7 (S.D 551516.6).
emergency room admissions and visits have a mean of 7826.7 (S.D 459.7). The number of
Opioid-related deaths has a mean of 960.3 (S.D 87.7). The number of Opioid Naïve patients
has a mean of 246686.0 (S.D 44921.5) and the number of prescriptions with Daily
MME>90 has a mean of 160448.0 (S.D 31173.9) as shown on Table 3.6 below.
Table 8
Descriptive statistics for Georgia-Data
Mean

Std Deviation

Std Error

Number of Opioid
RX’s

8,345,432.40

589,209.48

263,502.49

Number of ER
visits & admissions

8,306.60

827.47

370.06

RX Daily MME>90

189,745.20

47,129.56

21,076.98

Number of Opioid
Naïve Patients
Number of Opioid
Related Deaths

274,398.00

49,576.24

22,171.17

1,090.60

189.27

84.64
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To test the null hypothesis for the Research Questions 4 to 6 which states that there
is no association between community-based naloxone distribution (number of opioid
prescriptions written and dispensed; the number of opioid prescriptions with MME above
90; the number of opioid-naïve patients (thus patients who never used prescription opioids
in six months or more); the number of reported opioid overdoses; the number of addiction
treatments admissions; and the number of Opioid-related deaths, a one-way ANOVA was
conducted using SPSS software version 21 and post-hoc test using the Tukey HSD to
evaluate pairwise differences between means of the variables of the Georgia Data. The
results from the ANOVA revealed a significant difference in the mean of the variables with
F (4, 10) = 613.5 p<.001. See Table 3.7 below for details.
Table 9
One-way ANOVA for Georgia Data
Source

Sum of Squares

Df

Between
Groups

271013766929403.75 4

67753441732350.94 962.824

Within
Groups

1407390122022.40

70369506101.12

Total

272421157051426.16 24

20

Mean Square

F

Sig
.000
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Based on the post-hoc tests conducted, there is a significant difference between the
mean of the number of Prescription opioids per year and the mean of Emergency room
visits and admissions (mean difference= 8,337,125.80) with 95% C.I (7,835,085.93,
8,839,165.67). There is a significant difference between the mean of the number of
prescription Opioids per year and the mean of the number of prescriptions with Daily
MME>90 (mean difference= 8,155,687.20) with 95% C.I (7,653,647.33, 8,657,727.07).
There is a significant difference between the mean of the number of prescription opioids
per year and the mean of the number of Opioid Naïve Patients (mean difference=
8,071,034.40) with 95% C.I (7,568,994.53, 8,573,074.27).
There is a significant difference between the mean of the number of prescription
opioids per year and the mean of the number of Opioid-related deaths (mean difference=
8,344,341.80) with 95% C.I (7,842,301.93, 8,846,381.67). There is a significant difference
between the mean of the number of Emergency room admissions and visits and the mean
of the number of Prescription Opioid with Daily MME>90 (mean difference= -181438.60)
with 95% CI (-683,478.47, 320,601.27). There is a significant difference between the mean
of the number of Emergency room admissions and visits and the mean of the number of
Opioid Naïve Patients (mean difference -266091.40) with 95% CI (-768131.27,
235948.47).
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There is a significant difference between the mean of the number of emergency
room admissions and visits and the mean of the number of Opioid-related Deaths (mean
difference= 7216.00) with 95% CI (-494823.87, 509255.87). There is a significant
difference between the mean of the number of Prescriptions with Daily MME>90 and the
mean of Opioid Naïve Patients (mean difference= -84652.80) with 95% C.I (-586692.67 417387.07). There is a significant difference between the mean of the number of
Prescriptions with Daily MME>90 and the mean of the number of Opioid-related deaths
(mean difference 188654.60) with 95% CI (-313385.27, 690694.47). There is a significant
difference between the mean on the number of Opioid Naïve patients and the mean of the
number of Opioid-related deaths (mean difference = 273307.40) with 95% C I (-228732.47,
775347.27). See Table 3.8 for details.
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Table 10
Pairwise Differences in Mean and Corresponding 95% Confidence Intervals for Georgia
Data

Number of
Opioid RX’s
per year
Number of ER
visits &
admissions

Number of ER
visits &
admissions
8,337,125.80
(7,835,085.93,
8,839,165.67)

RX Daily
MME>90
8155687.20
(7,653,647.33,
8,657,727.07)

Number of
Opioid Naïve
Patients
8071034.40
(7,568,994.53,
8,573,074.27)

Number of
Opioid-Related
Deaths
8,344,341.80
(7,842,301.93,
8,846,381.67)

-181438.60 (683,478.47,
320,601.27)

-266091.40 (768131.27,
235948.47)

7216.00 (494823.87,
509255.87)

-84652.80 (586692.67, 417387.07)

188654.60 (313385.27,
690694.47
273307.40 (228732.47,
775347.27)

RX Daily
MME>90
Number of
Opioid Naïve
Patients
Number of
OpioidRelated Deaths
Table 11
Multiple Linear Regression, Florida Data
Model
Summary
Mode R

1

1.000a

R
Adjusted Std Error
Square R
of
Square
Estimate
1.000

R
Square
Change
1.000

Change Statistics
F
df1
df2 Sig F
DurbinChange
Change Watson
4

0

1.833
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Multiple linear regression test was performed to determine the influence of the
various independent variables on the dependent variable (The number of trained providers
in the PDMP per year from 2014 to 2018). From the above table, the R square value is
1.000. This shows the predictor values such as the number of prescriptions with daily
MME>90 from 2014 to 2018; the number of opioid prescriptions per year from 2014 to
2018 in Florida; the number of ER visits and admissions per year from 2014 to 2018 in
Florida; and the number of opioid-related deaths per year from 2014 to 2018 in Florida has
a significant influence on the number of trained providers in the PDMP. The DurbinWatson value of 1.833 is a health assumption that first-order linear auto-correction is
nonexistent in the multiple linear regression performed.
Table 12
Multiple Linear Regression, Georgia Data
Model
Summary
Mode R

1

1.000a

R
Adjusted Std Error
Square R
of
Square
Estimate
1.000

R
Square
Change
1.000

Change Statistics
F
df1
df2 Sig F
DurbinChange
Change Watson
4

0

Multiple linear regression test was also performed to determine the influence of
the various independent variables on the dependent variable (the number of opioid
prescriptions per year from 2014 to 2018). From the above table, the R square value is
1.000. This shows the predictor values such as the number of Opioid prescriptions with
Daily MME>90 per year from 2014 to 2018; the number of Opioid naive patients (thus
patients who have never used prescription opioids or haven't used it in the past 6 months

1.703
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or more); the total number of Opioid-related deaths from 2014 to 2018 in Georgia; the
total number of ER visits and admissions per year from 2014 to 2018 in Georgia has a
significant influence on the number of opioid prescriptions per year from 2014 to 2018 in
Georgia.
The Durbin-Watson value at 1.000 means that first-order linear auto-correlation
are nonexistent in the multiple linear regression performed.

Analysis of Research Questions
Research Question One
RQ1: Is there an association between the number of state-sponsored PDMPs trained
healthcare providers per year and the number of reported opioid overdoses per year among
adults 25 to 64 years?
Research Question Two
RQ2: Is there an association between the number of state-sponsored PDMPs trained
healthcare providers and the number of opioid addiction treatment admissions per year
among adults 25 to 64 years?
Research Question Three
RQ3: Is there an association between the number of state-sponsored PDMPs trained
healthcare providers and the number of deaths attributed to opioid overdose-related deaths
per year among adults 25 to 64 years?
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From the One-way ANOVA and the post-hoc analysis of the Florida data, it can be
said that the null hypothesis for Research Questions One to Three are false and that there
are significant differences between the mean of the variables. Research shows that
prescription opioid optimum therapeutic daily MME range is between 50 and 90
milligrams. Ranges above 90 milligrams have a high risk of overdose (Chua et al., 2020).
Research Question Four
RQ4: Is there an association between community-based naloxone distribution and
the number of reported opioid overdoses per year among adults 25 to 64 years?
Research Question Five
RQ5: Is there an association between community-based naloxone distribution and
the number of opioid addiction treatment admissions per year among adults 25 to 64 years?
Research Question Six
RQ6: Is there an association between community-based naloxone distribution and
the number of deaths attributed to opioid misuse/overdose per year among adults 25 to 64
years?
From the One-way ANOVA and the post-hoc analysis of the Georgia data, it can
be deduced that the null hypothesis for Research Questions Four to Six are also false and
that there are significant differences between the mean of the variables. According to Behar
et al. (2016) and Coffin et al. (2016), naloxone co-prescribing with prescription opioids is
associated with a reduction in opioid-related ER visits. Research also shows that the
implementation of the national opioid overdose and Naloxone Distribution (OEND) has
reduced the number of addiction treatment, hospital visits, and opioid-related mortality
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(Oliva et al., 2017). Furthermore, the distribution of naloxone kits in pharmacies and
hospitals per to state’s Public Health directors standing orders and protocols to allow nonpatient specific dispensing of naloxone have reduced opioid-related deaths (Bachyrycz et
al., 2018).
Summary
This research has demonstrated that the introduction of PDMPs and the Surgeon
Generals standing orders on Naloxone dispensing has had some effects on the considered
variables over the years compared. The introduction of the standard order prescription by
the Surgeon General in both states could contribute to the decline in ER visits and
admissions and the decline in opioid-related deaths in Georgia. However, the rise in opioidrelated deaths in Florida could be due to other confounding factors. The significance of
these results and how they can be applied towards positive social change would be
discussed in the next chapter.
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Section 4: Application to Professional Practice and Implications for Social Change
Introduction
The misuse of prescription opioids, including abuse, dependence, and overdose, is
well documented. According to the 2014 National Survey on Drug Use and Health, 15
million people aged 12 or older used prescription drugs non-medically in the past year. In
2013, there were 16,235 deaths from prescription opioid overdose. In 2014, the CDC
declared drug overdose deaths an epidemic (Florence et al., 2016; Kandel et al., 2017).
The opioid crisis has also resulted in a substantial cost burden to many communities and
states. The health care costs, criminal justice expenses, and productivity losses
attributable to opioid misuse were estimated to a total amount of $78.5 billion in 2014
alone (Chen et al., 2019).
In this study, I compared the state-sponsored PDMP data for Florida and Georgia.
The variables were the number of opioid prescriptions written each year, the number of
opioid prescriptions with MME above 90 each year, the number of opioid naïve patients
(patients who have never used opioid prescriptions or have not used it in the last 6
calendar months), the number of healthcare providers trained to use the PDMP, the
number of opioid-related emergency room visits and admissions each year, the number of
related opioid admissions into treatment centers each year, the number of opioid-related
deaths each year, and the gender and age of patients (age range between 25 and 64 years).
I found that most of the data for the variables correspond to both states.
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Socio-Ecological Model Theory
The SEM suggests that an individual’s behavior is integrated into a dynamic
network of intrapersonal characteristics, interpersonal processes, institutional factors,
community features, and public policy. The model stipulates that interactions between
individuals and their environment are reciprocal, implying that the individual is
influenced by their environment and the environment is influenced by the individual.
The SEM further assumes that the environment is comprised of different
overlapping levels. The intrapersonal level encompasses the research participant’s
knowledge, awareness, attitudes, beliefs, and perceptions. The individual’s family,
friends, and healthcare providers are important components of the interpersonal level.
The healthcare institution’s rules, regulations, and general attitude toward research
comprise the institutional level.
The community level includes local cultural attitudes, availability of public
amenities such as transportation, and safety of the neighborhood. The public policy level
includes local, state, and federal laws regarding socio-behavior. The SEM takes into
account socio-cultural factors, as well as environmental factors, and their linkages to
biologic factors.
Interpretation of the Findings
From the study on RQ1, I found that almost all the null hypotheses to research
questions were not valid, while the alternate hypothesis was right. There was however an
association between the state-sponsored PDMP trained healthcare providers and the
number of reported opioid overdoses among adults 25 to 64 years. It could be seen that in
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Florida as well the total number of prescription opioids dispensed decreased over the
years from 2014 to 2018. Also, in Georgia, the total number of prescription opioids with
a daily MME>90 decreased over the years.
On RQ2, the data shows that there is an association between the number of statesponsored PDMPs trained healthcare providers per year, the number of opioid addiction
treatment admissions, and the number of ER visits and admissions among adults 25 to 64
years (controlled for age group and gender). On RQ2, there was a relationship between
the PDMPs and the number of opioid addiction treatment admissions. The data showed
that the total number of ER visits and hospitalizations decreased between 2017 and 2018.
RQ3 only showed an association between the PDMP and deaths attributed to
opioid misuse/overdose in Georgia. The total number of opioid-related deaths decreased
between 2017 and 2018, as did opioid-related deaths by age range. In Florida, however,
the total number of opioid-related deaths increased between 2017 and 2018. This could
be due to the high incidence of illicit drugs such as synthetic fentanyl in the state.
RQ4 to RQ6 showed that the ready availability and accessibility of naloxone
through state health department standing order, and the ability of non-patients to purchase
naloxone without a prescription decreased the total number of opioid overdoses, which
reflects in the reduction of ER visits and admission as well as the number of opioidrelated deaths over the period.
Limitations of the Study
Florida started collecting public health data for its PDMP around 2012. However,
Georgia only began to collect data in 2014. Comparing two state-sponsored programs
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with different duration of implementation made the data analysis difficult. The Florida
health department has all data available to the general public, while the Georgia health
department requires Institutional Review Board application, which caused a delay in the
data gathering process.
Recommendation
Future research could include multiple states with varying demographics and
locations. Standardization of data reporting and regulations to all state-sponsored PDMPs
could influence any comparison research. From this current study, it was revealed that
there is a need for states to implement uniform and consistent public health policies and
guidelines across board to prevent cross-border travel to and from states with relaxed
policies.The licensure and continuing education requirements for healthcare providers on
prescribing prescription opioids should be adequate and extensive (Glowacki, 2015;
Lewis et al., 2015).
Implications for Professional Practice
Education and training of healthcare providers on prescription opioid prescribing
guidelines, proper medication, disposal systems, patient screening, doctor’s office urine
test, addiction treatment, and proper patient referral processes should be incorporated as
tools for the control and reduction of prescription opioid abuse/overdose. Furthermore,
appropriate policies and practices to prevent an increase in illicit opioid drug use such as
synthetic fentanyl and heroin could reduce opioid-related deaths in general (Hagemeier et
al., 2018; Stratton et al., 2018).
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Research has proven that opioid addiction has heritability rates similar to other
chronic diseases such as diabetes, asthma, and hypertension (Volkow & Mclellan, 2016).
Prescription opioid abuse is significantly affected by the lack of structural and social
determinants of health in the United States public health system. Healthcare providers are
either undereducated or misinformed about the appropriate use of prescription opioids for
non-cancer pain management and treatment (Dasgupta et al., 2018; Stratton et al., 2018).
Therefore, the need for comprehensive education along such lines is paramount.
Collaboration between healthcare providers to improve trustworthiness as well as
the use of the lowest effective for the shortest effective duration to achieve the
appropriate pain management would reduce prescription opioid abuse and reduce
addiction treatment cases (Volkow & Mclellan, 2016). The influence of the big drug
manufacturing companies on both state and federal authorities through lobbying and
funding of advocate group to push false narratives on non-cancer pain management has
contributed significantly to this prescription opioid epidemic (Stratton et al., 2018).
Social Change
Prescription opioid abuse has a disproportionately high prevalence among nonmetropolitan, suburban, and rural area populations due to the increased availability and
accessibility of prescription opioids by the older population. These medications have
become easily accessible to young family members who tend to abuse them (Faryar et al.,
2018). PDMPs, education of healthcare providers, and community use of naloxone and
practice guidelines have reduced misuse, abuse, addiction, diversion, and false
acquisition of prescription opioids (Pitt, Humphreys & Brandeau, 2018) There is a need
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for effective public health education using social media, print media, and the internet on
the effects of prescription opioid abuse/overdose on the population.
Lack of economic opportunities, poor working conditions, depression,
hopelessness, and lack of social capital are significant contributors to prescription opioid
abuse in many American communities (Dasgupta et al., 2018). The public health issue of
opioid abuse should be solved holistically with all social health determinants considered.
Pharmaceutical companies need to be tightly regulated and focused on their labeling,
post-marketing surveillance, abuse-deterrent formulations, and use of non-opioid
alternatives for non-cancer pain management.
Methods of overdose and addiction treatments as well use of counselors should be
reviewed continuously by the state PDMPs and public health authorities. Unfortunately,
recent research shows that the number of opioid prescriptions written in the United States
is roughly equal to the number of the adult population (Califf et al., 2016). The
management of non-cancer pain with cognitive behavioral therapy as well as a
complementary alternate medicine should be considered (Salas et al., 2016).
Conclusion
This research has demonstrated that the use of state-sponsored PDMPs,
availability and accessibility of naloxone, healthcare provider education, patient
screening, and abuse-deterrent formulations have a significant role in the reduction and
prevention of prescription opioid overdose among the population, especially those
between the ages of 25 and 64 years.
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